High-dose Chemotherapy and ASCT or Consolidating Conventional Chemotherapy in Primary CNS Lymphoma
NCT ID: NCT02531841
Last Updated: 2015-08-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE3
250 participants
INTERVENTIONAL
2014-07-31
2019-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
NCT05633615
Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma or Acute Lymphocytic Leukemia
NCT00002494
Gemcitabine and Hodgkin's Disease Chemotherapy Followed by Peripheral Blood Stem Cell Rescue for Hodgkin's Disease
NCT00388349
Rituximab, Combination Chemotherapy, Filgrastim (G-CSF), and Plerixafor in Treating Patients With Non-Hodgkin Lymphoma Undergoing Mobilization of Autologous Peripheral Blood Stem Cells
NCT01097057
Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma
NCT00601718
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
High-dose chemotherapy with carmustine or busulfan and thiotepa followed by autologous stem cell transplantation has been shown to be feasible and highly effective in newly diagnosed eligible patients, but also in the salvage situation.
The question we aim to answer is whether HDT-ASCT is superior to conventional therapy as consolidation after intensified immunochemotherapy in newly diagnosed PCNSL.
Rationale for this study:
Based on previously obtained good results from the treatment of recurrent or refractory PCNSL the DeVIC protocol was chosen for conventional consolidation treatment. This protocol, originally designed as a salvage protocol for aggressive NHL, crosses the blood-brain barrier and consists of multidrug resistant unrelated agents.
Treatment plan and procedure
Interventions
Induction treatment 4 cycles (every 3 weeks), stem-cell harvest after 2nd cycle:
* Rituximab 375 mg/m²/d i.v. (d 0,5)
* Methotrexate 3,5 g/m² i.v. (d1)
* Cytarabine 2 x 2 g/m²/d i.v. (d2-3)
* Thiotepa 30 mg/m² i.v. (d4)
Patients with PD after two cycles, SD/PD after four cycles of induction therapy or insufficient stem-cell harvest after three cycles are ineligible for randomization.
Consolidation Arm A 2 cycles of R-DeVIC (every 3 weeks):
* Rituximab 375 mg/m²/d i.v. (d0)
* Dexamethasone 40 mg/d i.v. (d1-3)
* Etoposide 100 mg/m²/d i.v. (d1-3)
* Ifosfamide 1500 mg/m²/d i.v. (d1-3)
* Carboplatin 300 mg/m² i.v. (d1)
Consolidation Arm B
High-dose chemotherapy (HDT-ASCT):
* Carmustine\* 400 mg/m² i.v. (d-6)
* Thiotepa 2 x 5 mg/kg/d i.v. (d-5-(-4))
* Autologous Stem Cell Transplantation (d0)
\* if carmustine is not available at the investigation site, busulfan can be administered instead:
* Busulfan 3,2 mg/kg/d (d-8-(-7))
* Thiotepa 2 x 5 mg/kg/d i.v. (d-5-(-4))
* Autologous Stem Cell Transplantation (d0)
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm A
Induction Treatment 4 cycles MATRix (every 3 weeks), stem-cell harvest after 2nd cycle:
* Rituximab 375 mg/m²/d i.v. (d0,5)
* Methotrexate 3.5 g/m² i.v. (d1)
* Cytarabine 2 x 2 g/m²/d i.v. (d2-3)
* Thiotepa 30 mg/m² i.v. (d4)
Consolidation Treatment 2 cycles of R-DeVIC (every 3 weeks):
* Rituximab 375 mg/m²/d i.v. (d0)
* Dexamethasone 40 mg/d i.v. (d1-3)
* Etoposide 100 mg/m²/d i.v. (d1-3)
* Ifosfamide 1500 mg/m²/d i.v. (d1-3)
* Carboplatin 300 mg/m² i.v. (d1)
Arm A (Fortecortin®-ETOPOPHOS®-IFO-cell®-CARBO-cell®)
Arm A 4 cycles MATRix (every 3 weeks), stem-cell harvest after 2nd cycle:
* Rituximab 375 mg/m²/d i.v. (d0,5)
* Methotrexate 3.5 g/m² i.v. (d1)
* Cytarabine 2 x 2 g/m²/d i.v. (d2-3)
* Thiotepa 30 mg/m² i.v. (d4) Consolidation 2 cycles of R-DeVIC (every 3 weeks):
* Rituximab 375 mg/m²/d i.v. (d0)
* Dexamethasone 40 mg/d i.v. (d1-3)
* Etoposide 100 mg/m²/d i.v. (d1-3)
* Ifosfamide 1500 mg/m²/d i.v. (d1-3)
* Carboplatin 300 mg/m² i.v. (d1)
Arm B
Induction Treatment 4 cycles MATRix (every 3 weeks), stem-cell harvest after 2nd cycle:
* Rituximab 375 mg/m²/d i.v. (d0,5)
* Methotrexate 3.5 g/m² i.v. (d1)
* Cytarabine 2 x 2 g/m²/d i.v. (d2-3)
* Thiotepa 30 mg/m² i.v. (d4)
Consolidation Treatment High-dose chemotherapy
* Carmustine\* 400 mg/m² i.v. (d-6)
* Thiotepa 2 x 5 mg/kg/d i.v. (d-5-(-4))
* Autologous Stem Cell Transplantation (d0)
\*if not available at study site, Busulfan can be administered instead:
* Busulfan 3,2 mg/kg/d i.v. (d-8-(-7))
* Thiotepa 2 x 5 mg/kg/d i.v. (d-5-(-4))
* Autologous Stem Cell Transplantation (d0)
Arm B (TEPADINA®-CARMUBRIS®-Busilvex®)
4 cycles MATRix (every 3 weeks), stem-cell harvest after 2nd cycle:
* Rituximab 375 mg/m²/d i.v. (d0,5)
* Methotrexate 3.5 g/m² i.v. (d1)
* Cytarabine 2 x 2 g/m²/d i.v. (d2-3)
* Thiotepa 30 mg/m² i.v. (d4) Consolidation
High-dose chemotherapy (HDT-ASCT):
* Carmustine\* 400 mg/m² i.v. (d-6)
* Thiotepa 2 x 5 mg/kg/d i.v. (d-5-(-4))
* Autologous Stem Cell Transplantation (d0)
\* if carmustine is not available at the investigation site, busulfan can be administered instead:
* Busulfan 3,2 mg/kg/d (d-8-(-7))
* Thiotepa 2 x 5 mg/kg/d i.v. (d-5-(-4))
* Autologous Stem Cell Transplantation (d0)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Arm A (Fortecortin®-ETOPOPHOS®-IFO-cell®-CARBO-cell®)
Arm A 4 cycles MATRix (every 3 weeks), stem-cell harvest after 2nd cycle:
* Rituximab 375 mg/m²/d i.v. (d0,5)
* Methotrexate 3.5 g/m² i.v. (d1)
* Cytarabine 2 x 2 g/m²/d i.v. (d2-3)
* Thiotepa 30 mg/m² i.v. (d4) Consolidation 2 cycles of R-DeVIC (every 3 weeks):
* Rituximab 375 mg/m²/d i.v. (d0)
* Dexamethasone 40 mg/d i.v. (d1-3)
* Etoposide 100 mg/m²/d i.v. (d1-3)
* Ifosfamide 1500 mg/m²/d i.v. (d1-3)
* Carboplatin 300 mg/m² i.v. (d1)
Arm B (TEPADINA®-CARMUBRIS®-Busilvex®)
4 cycles MATRix (every 3 weeks), stem-cell harvest after 2nd cycle:
* Rituximab 375 mg/m²/d i.v. (d0,5)
* Methotrexate 3.5 g/m² i.v. (d1)
* Cytarabine 2 x 2 g/m²/d i.v. (d2-3)
* Thiotepa 30 mg/m² i.v. (d4) Consolidation
High-dose chemotherapy (HDT-ASCT):
* Carmustine\* 400 mg/m² i.v. (d-6)
* Thiotepa 2 x 5 mg/kg/d i.v. (d-5-(-4))
* Autologous Stem Cell Transplantation (d0)
\* if carmustine is not available at the investigation site, busulfan can be administered instead:
* Busulfan 3,2 mg/kg/d (d-8-(-7))
* Thiotepa 2 x 5 mg/kg/d i.v. (d-5-(-4))
* Autologous Stem Cell Transplantation (d0)
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Age 18-65 years irrespective of ECOG or 66-70 years (with ECOG Performance Status ≤2)
3. Histologically or cytologically assessed diagnosis of B-cell lymphoma by local pathologist.
4. Diagnostic sample obtained by stereotactic or surgical biopsy, CSF cytology examination or vitrectomy
5. Disease exclusively located in the CNS
6. At least one measurable lesion
7. Previously untreated patients (previous or ongoing steroid treatment admitted)
8. Sexually active patients of childbearing potential who agree to take adequate contraceptive measures during study participation
9. Written informed consent obtained according to international guidelines and local laws by patient or authorized legal representative in case patient is temporarily legally not competent due to his or her disease
ADDITIONAL RANDOMIZATION CRITERIA
1. Sufficient stem cell harvest (≥ 5 x 106 CD34+ cells/kg of body weight)
2. Complete remission, unconfirmed complete remission or partial remission
3. Central pathology results confirming local results
Exclusion Criteria
2. Systemic lymphoma manifestation (outside the CNS)
3. Isolated ocular lymphoma without manifestation in the brain parenchyma or spinal cord
4. Previous or concurrent malignancies with the exception of surgically cured carcinoma in-situ of the cervix, carcinoma of the skin or other kinds of cancer without evidence of disease for at least 5 years
5. Previous Non-Hodgkin lymphoma at any time
6. Inadequate bone marrow (platelet count decreased ≥CTC grade 1, anemia ≥CTC grade 1, neutrophil count decreased ≥CTC grade 1), renal (creatinine clearance \<60 ml/min), cardiac (ejection fraction decreased ≥CTC grade 2), or hepatic function (blood bilirubin increased ≥CTC grade 2, alanine aminotransferase increased ≥CTC grade 2, aspartate aminotransferase increased ≥CTC grade 2 or gamma-GT increased ≥CTC grade 2)
7. HBsAg, anti-HBc or HCV positivity
8. HIV infection, previous organ transplantation or other clinical evident form of immunodeficiency
9. Concurrent treatment with other experimental drugs or participation in a clinical trial within the last thirty days before the start of this study
10. Symptomatic coronary artery disease, cardiac arrhythmias uncontrolled with medication or myocardial infarction within the last 6 months (New York Heart Association Class III or IV heart disease)
11. Severe non-compensated pulmonary disease (IVC \<55%, DLCO \<40%)
12. Third space fluid accumulation \>500 ml
13. Hypersensitivity to study treatment or any component of the formulation
14. Taking any medications likely to cause interactions with the study medication
15. Known or persistent abuse of medication, drugs or alcohol
16. Patient without legal capacity and who is unable to understand the nature, significance and consequences of the study and without designated legal representative
17. Persons who are in a relationship of dependency/employment to the sponsor and/ or investigator
18. Any familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule
19. Concurrent (or planned) pregnancy or lactation
20. Fertile patients refusing to use safe contraceptive methods during the study
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
German Federal Ministry of Education and Research
OTHER_GOV
International Extranodal Lymphoma Study Group (IELSG)
OTHER
University Hospital Freiburg
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Elisabeth Schorb
Medical Trial Coordinator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Gerald Illerhaus, PhD
Role: PRINCIPAL_INVESTIGATOR
Representative of Sponsor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospital Freiburg - Department for Hematology, Oncology and Stem cell Transplantion
Freiburg im Breisgau, Baden-Wurttemberg, Germany
Klinikum Stuttgart, Clinic of Hematology, Oncology and Palliative Care, Stuttgart Cancer Center / Tumor Center Eva Mayr-Stihl
Stuttgart, Baden-Wurttemberg, Germany
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Illerhaus G, Marks R, Ihorst G, Guttenberger R, Ostertag C, Derigs G, Frickhofen N, Feuerhake F, Volk B, Finke J. High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma. J Clin Oncol. 2006 Aug 20;24(24):3865-70. doi: 10.1200/JCO.2006.06.2117. Epub 2006 Jul 24.
Illerhaus G, Muller F, Feuerhake F, Schafer AO, Ostertag C, Finke J. High-dose chemotherapy and autologous stem-cell transplantation without consolidating radiotherapy as first-line treatment for primary lymphoma of the central nervous system. Haematologica. 2008 Jan;93(1):147-8. doi: 10.3324/haematol.11771.
Kasenda B, Schorb E, Fritsch K, Finke J, Illerhaus G. Prognosis after high-dose chemotherapy followed by autologous stem-cell transplantation as first-line treatment in primary CNS lymphoma--a long-term follow-up study. Ann Oncol. 2012 Oct;23(10):2670-2675. doi: 10.1093/annonc/mds059. Epub 2012 Apr 3.
Soussain C, Hoang-Xuan K, Taillandier L, Fourme E, Choquet S, Witz F, Casasnovas O, Dupriez B, Souleau B, Taksin AL, Gisselbrecht C, Jaccard A, Omuro A, Sanson M, Janvier M, Kolb B, Zini JM, Leblond V; Societe Francaise de Greffe de Moelle Osseuse-Therapie Cellulaire. Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Societe Francaise de Greffe de Moelle Osseuse-Therapie Cellulaire. J Clin Oncol. 2008 May 20;26(15):2512-8. doi: 10.1200/JCO.2007.13.5533. Epub 2008 Apr 14.
Motomura K, Natsume A, Fujii M, Ito M, Momota H, Wakabayashi T. Long-term survival in patients with newly diagnosed primary central nervous system lymphoma treated with dexamethasone, etoposide, ifosfamide and carboplatin chemotherapy and whole-brain radiation therapy. Leuk Lymphoma. 2011 Nov;52(11):2069-75. doi: 10.3109/10428194.2011.596967. Epub 2011 Jul 12.
Schorb E, Finke J, Ferreri AJ, Ihorst G, Mikesch K, Kasenda B, Fritsch K, Fricker H, Burger E, Grishina O, Valk E, Zucca E, Illerhaus G. High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma--a randomized phase III trial (MATRix). BMC Cancer. 2016 Apr 21;16:282. doi: 10.1186/s12885-016-2311-4.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DRKS00005503
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.